US5260438A - Method for removing the protecting group for hydroxy group - Google Patents

Method for removing the protecting group for hydroxy group Download PDF

Info

Publication number
US5260438A
US5260438A US08/052,680 US5268093A US5260438A US 5260438 A US5260438 A US 5260438A US 5268093 A US5268093 A US 5268093A US 5260438 A US5260438 A US 5260438A
Authority
US
United States
Prior art keywords
group
tri
substituted
fluoride
substituted silyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/052,680
Other languages
English (en)
Inventor
Hiroshi Horikawa
Kazuhiko Kondo
Tameo Iwasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Assigned to TANABE SEIYAKU CO., LTD. reassignment TANABE SEIYAKU CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HORIKAWA, HIROSHI, IWASAKI, TAMEO, KONDO, KAZUHIKO
Application granted granted Critical
Publication of US5260438A publication Critical patent/US5260438A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D463/02—Preparation
    • C07D463/06—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a novel method for removing the protecting group for hydroxy group.
  • ⁇ -Lactam compounds having a hydroxy group have been known to be useful as an antimicrobial agent having excellent antimicrobial activity or an intermediate thereof.
  • various ⁇ -lactam antimicrobials such as penem antimicrobials [cf. Japanese Patent Second Publication (Kokoku) No. 396/1991, Japanese Patent First Publication (Kokai) No. 105686/1980, Japanese Patent Second Publication (Kokoku) No. 14679/1992], carbapenem antimicrobials [cf. Japanese Patent First Publication (Kokai) No. 202886/1985, Japanese Patent First Publication (Kokai) No. 5081/1986, Japanese Patent First Publication (Kokai) No.
  • methods 1), 2) and 3) are used for removal of t-butyldimethylsilyl group
  • method 4 method 5) and method 6) are used for removal of t-butyldiphenyl silyl group, triethylsiliyl group and trimethylsilyl group, respectively.
  • An object of the present invention is to provide a novel method for removing the protecting groups for hydroxy group. More particularly, the present invention provides a novel method for removing effectively tri-substituted silyl groups from a compound having a tri-substituted silyl group-protecting hydroxy group without decomposition of the desired product, even though the such compound has an unstable structure, such as ⁇ -lactam compounds.
  • the removal of the protecting group from a ⁇ -lactam compound having a tri-substituted silyl group-protecting hydroxy group is carried out by treating said ⁇ -lactam compound with a combination of a fluoride selected from a) an alkali metal fluoride, b) an alkaline earth metal fluoride, and c) a hydrogenfluoride with an inorganic or organic amine, and an acid.
  • a fluoride selected from a) an alkali metal fluoride, b) an alkaline earth metal fluoride, and c) a hydrogenfluoride with an inorganic or organic amine, and an acid.
  • the "fluoride” includes, for example, a) alkali metal fluorides such as potassium fluoride, sodium fluoride, cesium fluoride, etc., b) alkaline earth metal fluorides such as calcium fluoride, etc., c) hydrogenfluorides of an inorganic or organic amine such as ammonium fluoride, a tri-lower alkylammonium fluoride, a benzyl(di-lower alkyl)ammonium fluoride, pyridinium fluoride, etc.
  • the “acid” may be any strong or weak organic or inorganic acids, for example, lower alkanoic acids (e.g. acetic acid, propionic acid, butyric acid, etc.), hydroxy-substituted lower alkanoic acids (e.g. citric acid, etc.), trihalogeno-lower alkanoic acids (e.g. trifluoroacetic acid, etc.), lower alkanesulfonic acids (e.g. methanesulfonic acid, etc.), phenylsulfonic acids which may optionally be substituted by a lower alkyl group or a halogen atom (e.g. p-toluenesulfonic acid, benzenesulfonic acid, etc.), mineral acids (e.g. hydrofluoric acid, hydrobromic acid, sulfuric acid, hydrochloric acid, etc.), and the like.
  • lower alkanoic acids e.g. acetic acid, propionic acid, buty
  • fluorides and acids may be used in any form, for example, in the form of a mixture of a fluoride and an acid, or in the form of a compound consisting of these two components including a salt, a double salt, a complex, an adduct, etc.
  • the fluoride is used in an amount sufficient to remove the tri-substituted silyl group, for example, it is usually used in an amount of 1 to 10 equivalents, more preferably 4 to 8 equivalents to the starting compound.
  • the amount of the acid varies according to acidity of the acid to be used, but it is usually used in an amount sufficient to keep the pH value of the reaction solution pH 2 to 7, preferably pH 4 to 7, for example, it is usually used in an amount of 0.01 to 10 equivalents, preferably 0.01 to 8 equivalents to the starting compound.
  • the fluoride is any one as mentioned above, but alkali metal fluorides, alkaline earth metal fluorides, and ammonium fluoride are preferable.
  • the acid is any one as mentioned above, but lower alkanoic acids and mineral acids are preferable.
  • the mixture of the fluoride and the acid is, for example, a mixture of an alkali metal fluoride and a lower alkanoic acid, a mixture of an alkaline earth metal fluoride and a lower alkanoic acid, and a mixture of ammonium fluoride and a mineral acid.
  • the compound may be any one which contains both a fluoride and an acid as a component, such as a compound wherein these two components act not independently but cooperatively in the reaction system, and a compound wherein said acid does not exist in the form of an acid in the reaction system.
  • Suitable examples of the compound are compounds consisting of a fluoride selected from an alkali metal fluoride, an alkaline earth metal fluoride and a hydrogenfluoride of an inorganic or organic amine such as ammonium hydrogenfluoride (NH 4 F.HF) and alkali metal hydrogenfluorides [e.g.
  • KF.HF potassium hydrogenfluoride
  • NaF.HF sodium hydrogenfluoride
  • hydrogen fluoride hydrogen fluoride
  • the compound is used in an amount wherein each component is contained in an amount as mentioned above, and the compound is preferably used in an amount of 1 to 10 equivalents, more preferably 4 to 8 equivalents to the starting compound.
  • the reaction can be carried out under cooling or with heating, for example, at 0° C., to 50° C., preferably at 15° C. to 25° C., in a solvent.
  • the solvent may be any one which does not affect the reaction, polar solvents are preferable.
  • the polar solvent includes, for example, organic solvents such as dimethylformamide, acetonitrile, tetrahydrofuran, dimethylsulfoxide, dimethylacetamide, or a mixture of water and these organic solvents.
  • the alkali metal fluoride or alkaline earth metal fluoride may be either in the form of an anhydride thereof or in the form of a hydrate thereof (e.g. potassium fluoride dihydrate).
  • the solvent used in the reaction is preferably a mixture of water and the above mentioned organic solvent, and water is used in an mount of 1 to 10 equivalents, preferably 2 to 8 equivalents to the alkali metal fluoride or alkaline earth metal fluoride.
  • the ⁇ -lactam compound having a tri-substituted silyl group-protecting hydroxy group may be any conventional ⁇ -lactam compound, for example, a compound having a partial structure of the formula [I]: ##STR1## wherein R is a tri-substituted silyl group, and Alk is a straight chain or branched chain lower alkylene group, more particularly, a compound of the formula [I-a]: ##STR2## wherein R 1 is an organic group, a group of the formula: --COOR 2 is a protected or unprotected carboxyl group, X is a group of the formulae: --CH 2 CH 2 --, --S--CH 2 --, --O--CH 2 --, --CH 2 --, --CH(R 3 )--, --S-- or --O--, in which R 3 is a lower alkyl group, and Y is a sulfur atom, oxygen atom, or single bond, and R and Alk are
  • ⁇ -lactam compounds are useful as antimicrobials, prodrugs thereof, or intermediate thereof.
  • the organic group represented by R 1 in the formula [I-a] may be any one which is used for conventional ⁇ -lactam antimicrobials, for example, lower alkyl groups, cycloalkyl groups, aryl groups (e.g. phenyl group, etc.), heterocyclic groups having at least one heteroatom selected from nitrogen atom, oxygen atom or sulfur atom (e.g. pyrrolidinyl group, piperidinyl group, furyl group, thienyl group, imidazolinyl group, pyridyl group, etc.), and the like.
  • aryl groups e.g. phenyl group, etc.
  • heterocyclic groups having at least one heteroatom selected from nitrogen atom, oxygen atom or sulfur atom e.g. pyrrolidinyl group, piperidinyl group, furyl group, thienyl group, imidazolinyl group, pyridyl group, etc.
  • these groups may optionally have one or more substituents, and the substituent includes, for example, hydroxy group, a lower alkyl group, an amino-lower alkyl group, a lower alkoxy group, amino group, a lower alkylamino group, mercapto group, a lower alkylthio group, amidino group, guanidino group, carbamoyl group, thiocarbamoyl group, sulfamoyl group, carbamoyloxy group, cyano group, carboxyl group, a lower alkoxycarbonyl group, an aralkyloxycarbonyl group, oxo group, thioxo group, a halogeno group, a cycloalkyl group, an aryl group (e.g.
  • phenyl group etc.
  • a heterocyclic group e.g. pyrrolidinyl group, piperidinyl group, furyl group, thienyl group, imidazolinyl group, pyridyl group, etc.
  • a heterocyclic group e.g. pyrrolidinyl group, piperidinyl group, furyl group, thienyl group, imidazolinyl group, pyridyl group, etc.
  • the protecting group for the carboxyl group may be any conventional one, for example, groups which can be used for prodrugs of ⁇ -lactam antimicrobials, or groups which can be removed during the synthesis of ⁇ -lactam antimicrobials.
  • the groups which can be used for prodrugs of ⁇ -lactam antimicrobials are, for example, ester residues which are metabolized in living body by hydrolysis, and the like, for example, groups of the formulae: --Z--OCOR 4 , --Z--OCO 2 R 4 and --Z--O--R 4 (in which Z is a lower alkylene group, R 4 is a lower alkyl group, a cycloalkyl group, a lower alkenoyl group, a lower alkoxy-lower alkyl group, a lower alkanoyloxy-lower alkyl group).
  • Suitable examples of these groups are a lower alkanoyloxy-lower alkyl group, a cycloalkylcarbonyloxy-lower alkyl group, a lower alkenoyloxy-lower alkyl group, a lower alkoxy-lower alkanoyloxy-lower alkyl group, a lower alkanoyloxy-lower alkoxy-lower alkyl group, a lower alkoxy-lower alkyl group, a lower alkoxy-lower alkoxy-lower alkyl group, a lower alkoxycarbonyloxy-lower alkyl group, a lower alkoxy-lower alkoxycarbonyloxy-lower alkyl group.
  • the groups which can be removed during the synthesis of ⁇ -lactam antimicrobials may be any conventional one, for example, a lower alkyl group, a lower alkenyl group, a halogeno-lower alkyl group, nitrobenzyl group, and a lower alkoxybenzhydryl group.
  • the "tri-substituted silyl group" used for protecting hydroxy group is silyl groups which are substituted by three groups selected from a straight chain or branched chain lower alkyl group and phenyl group, for example, tri-lower alkylsilyl groups (e.g. trimethylsilyl group, triethylsilyl group, etc.), branched chain lower alkyl group-substituted di-lower alkylsilyl groups (e.g. t-butyldimethylsilyl group, etc.), lower alkyl group-substituted di-branched chain lower alkylsilyl group (e.g.
  • methyldiisopropylsilyl group, etc. methyldiisopropylsilyl group, etc.
  • branched chain lower alkyl group-substituted diphenylsilyl groups e.g. t-butyldiphenylsilyl group, etc.
  • triphenylsilyl group e.g. t-butyldiphenylsilyl group, etc.
  • tri-substituted silyl group having 6 to 18 carbon atoms especially, branched chain lower alkyl group-substituted di-lower alkylsilyl groups, lower alkyl group-substituted di-branched chain lower alkylsilyl groups, branched chain lower alkyl group-substituted diphenylsilyl group, triphenylsilyl group are preferable, and branched chain lower alkyl group-substituted di-lower alkylsilyl groups are more preferable.
  • the "lower alkyl” group, the “lower alkylene group” and the “lower alkoxy group” are ones having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, respectively.
  • the "lower alkanoyl group” and the “lower alkenyl group” are ones having 2 to 7 carbon atoms, preferably 2 to 5 carbon atoms, respectively.
  • the “lower alkenoyl group” and the “cycloalkyl group” are ones having 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms, respectively.
  • the "lower alkanoic acid” is ones having 2 to 7 carbon atoms, preferably 2 to 5 carbon atoms
  • the “lower alkanesulfonic acid” is ones having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms.
  • Example 1 The same procedures as Example 1 are repeated except that calcium fluoride is used instead of potassium fluoride to give (1R,5S,6S)-2-[(4R)-pyrrolidine-2-thion-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid isobutyryloxymethyl ester.
  • Example 2 The same procedures as Example 1 are repeated except that hydrobromic acid and ammonium fluoride are used instead of acetic acid and potassium fluoride to give (1R,5S,6S)-2-[(4R)-pyrrolidine-2-thion-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid isobutyryloxymethyl ester.
  • Example 2 The same procedures as Example 1 are repeated except that sulfuric acid and ammonium fluoride are used instead of acetic acid and potassium fluoride to give (1R,5S,6S)-2-[(4R)-pyrrolidine-2-thion-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid isobutyryloxymethyl ester.
  • Example 2 The same procedures as Example 2 are repeated except that potassium hydrogenfluoride is used instead of ammonium hydrogenfluoride to give (1R,5S,6S)-2-[(4R)-pyrrolidine-2-thion-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid ally ester.
  • (3S,4S)-3-[(1R)-1-t-Butyldimethylsilyloxyethyl]-4-[(1S)-1-phenylthiocarbonylethyl]-1-(1-methoxycarbonylmethyl)-2-azetidinone is treated in the same manner as in Example 1, 2 or 3 to give (3S,4S)-3-[(1R)-1-hydroxyethyl]-4-[(1S)-1-phenylthiocarbonylethyl]-1-(1-methoxycarbonylmethyl)-2-azetidinone.
  • tri-substituted silyl groups are effectively removed under moderate conditions from a compound having tri-substituted silyl group-protecting hydroxy group, even though said compound has an unstable structure such as ⁇ -lactam compounds, so that the desired compound can be obtained easily and in high yield without decomposition of the desired compounds.
  • the method of the present invention is industrially useful as a method for removing protecting groups for hydroxy group.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US08/052,680 1992-04-28 1993-04-27 Method for removing the protecting group for hydroxy group Expired - Lifetime US5260438A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP15404292 1992-04-28
JP28860592 1992-10-27
JP31739592 1992-11-26

Publications (1)

Publication Number Publication Date
US5260438A true US5260438A (en) 1993-11-09

Family

ID=27320582

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/052,680 Expired - Lifetime US5260438A (en) 1992-04-28 1993-04-27 Method for removing the protecting group for hydroxy group

Country Status (3)

Country Link
US (1) US5260438A (de)
EP (2) EP0567949B1 (de)
DE (1) DE69329939T2 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821362A (en) * 1993-02-12 1998-10-13 Suntory Limited Method of desilylating silylether compounds
WO2011048583A1 (en) 2009-10-23 2011-04-28 Ranbaxy Laboratories Limited Process for the preparation of carbapenem compounds
US20110224426A1 (en) * 2008-07-30 2011-09-15 Neera Tewari Process for the preparation of carbapenem compounds
US10695322B2 (en) 2016-01-29 2020-06-30 The Johns Hopkins University Inhibitors of bacterial growth

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4174316A (en) * 1978-08-14 1979-11-13 Merck & Co., Inc. 4-Iodomethylazetidin-2-one
JPS5569586A (en) * 1978-10-24 1980-05-26 Merck & Co Inc 11* 66 and 22substitutedd11carbaa22penenn 33carboxylic acid
JPS55105686A (en) * 1979-01-10 1980-08-13 Schering Corp Organic compound*its manufacture and medical composition containing it
JPS57123182A (en) * 1980-12-18 1982-07-31 Merck & Co Inc 6- and 4-substituted-1-azabicyclo(3,1,2,0)heptane- 3,7-dione-2-carboxylate
JPS58103358A (ja) * 1981-10-23 1983-06-20 メルク・エンド・カムパニ−・インコ−ポレ−テツド 抗生物質中間体の製造方法
JPS60202886A (ja) * 1984-03-27 1985-10-14 Sankyo Co Ltd １―置換カルバペネム―３―カルボン酸誘導体
JPS60233077A (ja) * 1984-04-23 1985-11-19 メルク　エンド　カムパニー　インコーポレーテツド １‐テヘロ‐６‐〔１‐ヒドロキシエチル〕‐２‐ｓｒ↑８‐１‐カルバデチアペン‐２‐エム‐３‐カルボン酸
JPS615081A (ja) * 1984-06-18 1986-01-10 Sankyo Co Ltd １−置換カルバペネム−３−カルボン酸誘導体の製造法
JPS6254427A (ja) * 1985-07-31 1987-03-10 Nec Corp 半導体装置の製造方法
JPS62103084A (ja) * 1984-12-27 1987-05-13 Sumitomo Pharmaceut Co Ltd β−ラクタム化合物の製造方法
JPS6479147A (en) * 1979-07-23 1989-03-24 Merck & Co Inc Intermediate for synthesis of thienamycin
JPH03396A (ja) * 1989-05-02 1991-01-07 Dart Eng Ag カップリング装置
JPH0414679A (ja) * 1990-05-07 1992-01-20 Pioneer Electron Corp データ再生処理装置
EP0474243A1 (de) * 1990-09-07 1992-03-11 Tanabe Seiyaku Co., Ltd. 1-Methylcarbapenemderivate und Verfahren zu ihrer Herstellung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA80993B (en) 1979-02-24 1981-02-25 Erba Farmitalia -lactam-containing antibacterial agents and -lactamase inhibitors and preparation thereof
CA1190236A (en) * 1981-10-23 1985-07-09 Edward J.J. Grabowski Antibiotic synthesis
JPS5951286A (ja) 1982-09-10 1984-03-24 Sankyo Co Ltd カルバペネム誘導体の製造法
GB8300295D0 (en) 1983-01-06 1983-02-09 Erba Farmitalia Penem esters

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4174316A (en) * 1978-08-14 1979-11-13 Merck & Co., Inc. 4-Iodomethylazetidin-2-one
JPS5569586A (en) * 1978-10-24 1980-05-26 Merck & Co Inc 11* 66 and 22substitutedd11carbaa22penenn 33carboxylic acid
JPS55105686A (en) * 1979-01-10 1980-08-13 Schering Corp Organic compound*its manufacture and medical composition containing it
JPS6479147A (en) * 1979-07-23 1989-03-24 Merck & Co Inc Intermediate for synthesis of thienamycin
JPS57123182A (en) * 1980-12-18 1982-07-31 Merck & Co Inc 6- and 4-substituted-1-azabicyclo(3,1,2,0)heptane- 3,7-dione-2-carboxylate
JPS58103358A (ja) * 1981-10-23 1983-06-20 メルク・エンド・カムパニ−・インコ−ポレ−テツド 抗生物質中間体の製造方法
JPS60202886A (ja) * 1984-03-27 1985-10-14 Sankyo Co Ltd １―置換カルバペネム―３―カルボン酸誘導体
JPS60233077A (ja) * 1984-04-23 1985-11-19 メルク　エンド　カムパニー　インコーポレーテツド １‐テヘロ‐６‐〔１‐ヒドロキシエチル〕‐２‐ｓｒ↑８‐１‐カルバデチアペン‐２‐エム‐３‐カルボン酸
JPS615081A (ja) * 1984-06-18 1986-01-10 Sankyo Co Ltd １−置換カルバペネム−３−カルボン酸誘導体の製造法
JPS62103084A (ja) * 1984-12-27 1987-05-13 Sumitomo Pharmaceut Co Ltd β−ラクタム化合物の製造方法
JPS6254427A (ja) * 1985-07-31 1987-03-10 Nec Corp 半導体装置の製造方法
JPH03396A (ja) * 1989-05-02 1991-01-07 Dart Eng Ag カップリング装置
JPH0414679A (ja) * 1990-05-07 1992-01-20 Pioneer Electron Corp データ再生処理装置
EP0474243A1 (de) * 1990-09-07 1992-03-11 Tanabe Seiyaku Co., Ltd. 1-Methylcarbapenemderivate und Verfahren zu ihrer Herstellung

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. G. M. Barrett, S. Sakadarat, "Total Syntheses of Penicillanic Acid S,S-Dioxide and 6-Aminopenicillanic Acid Using (Benzyloxy)nitromethane", J. Org. Chem., 55, 5110-5117 1990.
A. G. M. Barrett, S. Sakadarat, Total Syntheses of Penicillanic Acid S,S Dioxide and 6 Aminopenicillanic Acid Using (Benzyloxy)nitromethane , J. Org. Chem., 55, 5110 5117 1990. *
M. Imuta, et al. "Carbapenem and Penem Antibiotics. VI. Synthesis and Antibacterial Activity of 2-Heteroaromatic-thiomethys and 2-Carbamoyloxymethyl 1-Methylcarbapenems", Chem. Pharm. Bull. 39(3) 663-671.
M. Imuta, et al. Carbapenem and Penem Antibiotics. VI. Synthesis and Antibacterial Activity of 2 Heteroaromatic thiomethys and 2 Carbamoyloxymethyl 1 Methylcarbapenems , Chem. Pharm. Bull. 39(3) 663 671. *
S. Hanessian, D. Desilets, Y. Bennani, "A Novel Ring-Closure Strategy for the Carbapenems: The Total thesis of (+)-Thienamycin", J. Org. Chem., 55, 3098-3103 1990.
S. Hanessian, D. Desilets, Y. Bennani, A Novel Ring Closure Strategy for the Carbapenems: The Total thesis of ( ) Thienamycin , J. Org. Chem., 55, 3098 3103 1990. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821362A (en) * 1993-02-12 1998-10-13 Suntory Limited Method of desilylating silylether compounds
US20110224426A1 (en) * 2008-07-30 2011-09-15 Neera Tewari Process for the preparation of carbapenem compounds
US8841444B2 (en) 2008-07-30 2014-09-23 Ranbaxy Laboratories Limited Process for the preparation of carbapenem compounds
WO2011048583A1 (en) 2009-10-23 2011-04-28 Ranbaxy Laboratories Limited Process for the preparation of carbapenem compounds
US10695322B2 (en) 2016-01-29 2020-06-30 The Johns Hopkins University Inhibitors of bacterial growth

Also Published As

Publication number Publication date
EP0937725A3 (de) 2004-12-01
EP0567949A1 (de) 1993-11-03
DE69329939T2 (de) 2001-06-28
EP0567949B1 (de) 2001-02-21
EP0937725A2 (de) 1999-08-25
DE69329939D1 (de) 2001-03-29

Similar Documents

Publication Publication Date Title
US4631150A (en) Process for the preparation of penems
US5589592A (en) Process for preparing β-lactam derivative and synthetic intermediate
EP0110280B1 (de) Verfahren zur Herstellung von Penem-Verbindungen
US5587474A (en) Method for removing the protecting group for carboxyl group
EP0146730A1 (de) Verfahren zur Herstellung von Penemen
US5260438A (en) Method for removing the protecting group for hydroxy group
US4395418A (en) Penem-3-carboxylic acid derivatives
EP0679652B1 (de) Verfahren zur Herstellung von Carbapenem-Verbindungen
US4690922A (en) 2-(heterocycloalkylthio)penems
KR101031143B1 (ko) 경구 투여용 카르바페넴 화합물의 신규 합성 중간체 및그의 제조 방법
JP2689412B2 (ja) 保護基の除去方法
US4841043A (en) Stereoselective synthesis of 1-β-alkyl carbapenem antibiotic intermediates
US5359059A (en) Process for preparing carbapenem derivatives
KR880001989B1 (ko) 펜엠 화합물의 제조방법
US4769451A (en) Synthesis of carbapenems using n-substituted azetidinones
JPH0853404A (ja) ４，４−ジアルキル−２−アゼチジノン類の新規中間体
JPH0625243A (ja) １−メチルカルバペネム誘導体の製造法
JP2643753B2 (ja) ２−オキシカルバペネム誘導体の製法
US4973687A (en) Synthesis of carbapenems using N-substituted azetidinones
US6153747A (en) Process for the preparation of 2-halomethyl-penems and their use for the preparation of antibacterial penems
US4554103A (en) Preparation of 4-acyloxyazetidinones from acyl nitrates and penams
JP2000191680A (ja) カルバペネム誘導体およびその製造方法
JPH07316160A (ja) カルバペネム化合物の製造方法
Yoshioka et al. 3-(CHFCH 3)-azetidinone intermediates
JP2000191679A (ja) カルバペネム誘導体およびその製造方法

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

AS Assignment

Owner name: TANABE SEIYAKU CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HORIKAWA, HIROSHI;KONDO, KAZUHIKO;IWASAKI, TAMEO;REEL/FRAME:006579/0252

Effective date: 19930414

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12